What is the recommended dose of Toradol (ketorolac) for back pain administered intramuscularly (IM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended IM Dose of Toradol (Ketorolac) for Back Pain

For adults under 65 years with normal renal function and body weight ≥50 kg, administer 60 mg IM as a single dose for acute back pain. 1

Standard Dosing Protocol

Single-Dose Treatment (Most Common for Acute Back Pain)

  • Adults <65 years: 60 mg IM as a single dose 1
  • Adults ≥65 years, renally impaired, or <50 kg body weight: 30 mg IM as a single dose 1
  • Administer slowly and deeply into the muscle 1
  • Analgesic effect begins in approximately 30 minutes, with maximum effect at 1-2 hours 1
  • Duration of analgesia is typically 4-6 hours 1

Multiple-Dose Treatment (If Continued Therapy Required)

  • Adults <65 years: 30 mg IM every 6 hours (maximum 120 mg/day) 1
  • Adults ≥65 years, renally impaired, or <50 kg: 15 mg IM every 6 hours (maximum 60 mg/day) 1
  • Critical limitation: Total duration must not exceed 5 days 1, 2
  • Switch to alternative analgesics as soon as possible 1

Evidence Supporting This Dosing

The 60 mg IM dose is well-established in clinical practice despite evidence suggesting lower doses may provide similar analgesia. Research demonstrates that ketorolac exhibits an analgesic ceiling effect, with 10 mg potentially being the ceiling dose 3. However, the FDA-approved dosing remains 60 mg IM for single-dose treatment in younger adults 1.

Clinical Trial Data for Back Pain

  • Ketorolac (10 mg oral) provided comparable analgesia to morphine (5-10 mg IM) for postoperative orthopedic pain 4
  • Ketorolac (60 mg IM) showed comparable efficacy to meperidine (1 mg/kg IM) for severe musculoskeletal low back pain, with 63% of patients achieving ≥30% pain reduction 5
  • Ketorolac (10 mg oral every 4-6 hours) was superior to acetaminophen-codeine for acute low back pain in the ED, with fewer adverse events 6

Critical Safety Considerations

Mandatory contraindications and precautions:

  • Correct hypovolemia before administration 1
  • Avoid in patients with aspirin/NSAID-induced asthma 2
  • Avoid in pregnant patients 2
  • Avoid in patients with cerebrovascular hemorrhage 2
  • Do not use with curative doses of anticoagulants 2
  • Reduce dose by 50% in elderly (≥65 years), renally impaired, or patients <50 kg 1

Common adverse effects include:

  • Edema, drowsiness, dizziness 2
  • Gastrointestinal upset 2
  • Increased sweating 2
  • Dose-related gastric ulcerations (even with parenteral administration) 7
  • Reversible platelet aggregation inhibition 7

Clinical Pearls

The 60 mg IM dose remains standard practice despite the analgesic ceiling effect, as demonstrated by a 10-year retrospective study showing 97% of IV doses and 96% of IM doses were prescribed above the theoretical 10 mg ceiling 3. The FDA-approved dosing should guide initial treatment 1.

For breakthrough pain, do not increase dose or frequency of ketorolac 1. Instead, consider supplementing with low-dose opioids unless contraindicated 1.

Ketorolac offers advantages over opioids for musculoskeletal back pain, including comparable analgesic efficacy with significantly fewer adverse events, less sedation, and no risk of respiratory depression 6, 5.

References

Guideline

Safety of 60 mg Toradol (Ketorolac) for Initial Pain Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Patterns of Ketorolac dosing by emergency physicians.

World journal of emergency medicine, 2017

Research

Ketorolac versus meperidine: ED treatment of severe musculoskeletal low back pain.

The American journal of emergency medicine, 2000

Research

Ketorolac: a parenteral nonsteroidal antiinflammatory drug.

DICP : the annals of pharmacotherapy, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.